Plasma cell neoplasms in US solid organ transplant recipients

American Journal of Transplantation

Volumn 13, Issue 6, 2013, Pages 1523-1532

  Engels, E A ^a   Clarke, C A ^b   Pfeiffer, R M ^a   Lynch, C F ^c   Weisenburger, D D ^d   Gibson, T M ^a   Landgren, O ^a   Morton, L M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Epstein Barr virus; immunosuppression; multiple myeloma; plasmacytoma; posttransplant lymphoproliferative disorder; primary biliary cirrhosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BILIARY CIRRHOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CHILD; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; INFANT; INTRAHEPATIC CHOLESTASIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEWBORN; ORGAN TRANSPLANTATION; PLASMACYTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PLASMACYTOMA; POSTOPERATIVE PERIOD; REGISTRIES; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84878484939     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12234     Document Type: Article

References (49)

1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM., Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370: 59-67.
2. Engels EA, Pfeiffer RM, Fraumeni JF Jr., Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901.
3. Andreone P, Gramenzi A, Lorenzini S, Biselli M, Cursaro C, Pileri S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003; 163: 1997-2004.
4. Swerdlow SH, Webber SA, Chadburn A, Ferry JA., Post-transplant lymphoproliferative disorder. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008, pp. 343-349.
5. Opelz G, Daniel V, Naujokat C, Dohler B., Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
6. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-1227.
7. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831.
8. Collett D, Mumford L, Banner NR, Neuberger J, Watson C., Comparison of the incidence of malignancy in recipients of different types of organ: A UK registry audit. Am J Transplant 2010; 10: 1889-1896.
9. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y., Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007; 7: 941-948.
10. McKenna RW, Kyle RA, Kuehl RA, Grogan TM, Harris NL, Coupland RW., Plasma cell neoplasms. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008, pp. 200-213.
11. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS., Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: Incidence and survival in the United States, 1992-2004. Br J Haematol 2009; 144: pp. 86-94.
12. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al. Racial disparities in incidence and outcome in multiple myeloma: A population-based study. Blood 2010; 116: pp. 5501-5506.
13. Penfield JG., Multiple myeloma in end-stage renal disease. Semin Dial 2006; 19: 329-334.
14. Vajdic CM, van Leeuwen MT., Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-1754.
15. Sun X, Peterson LC, Gong Y, Traynor AE, Nelson BP., Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients. Mod Pathol 2004; 17: 389-394.
16. Papadaki HA, Stefanaki K, Kanavaros P, Katonis P, Papastathi H, Valatas W, et al. Epstein-Barr virus-associated high-grade anaplastic plasmacytoma in a renal transplant patient. Leuk Lymphoma 2000; 36: 411-415.
17. Schemankewitz E, Hammami A, Stahl R, Henderson JM, Check IJ., Multiple extramedullary plasmacytomas following orthotopic liver transplantation in a patient on cyclosporine therapy. Transplantation 1990; 49: 1019-1022.
18. Gupta A, Shenton BK, Gok MA, Wilson C, Asher J, Hide G, et al. Plasma cell myeloma variant of post-transplant lymphoproliferative disorder in a solid organ transplant recipient: A case report. Nephrol Dial Transplant 2004; 19: 3186-3189.
19. Ancin I, Sarra J, Peris J, Romagosa V, Domingo-Claros A, Granena A., Demonstration of Epstein-Barr virus in a case of multiple myeloma after renal transplantation. Haematologica 2000; 85: 773-774.
20. Taheri D, Chehrei A, Fesharakizadeh M, Seyrafean S, Shahidi S, Emami A, et al. Recurrent multiple myeloma following renal transplantation: A case report. Transplant Proc 2007; 39: 1063-1065.
21. Tcheng WY, Said J, Hall T, Al-Akash S, Malogolowkin M, Feig SA., Post-transplant multiple myeloma in a pediatric renal transplant patient. Pediatr Blood Cancer 2006; 47: 218-223.
22. Peri N, Kussick S, Bakthavatsalam R, Mitsumori L, Dighe M., Postrenal transplant non-EBV multiple myeloma of donor origin. Am J Transplant 2006; 6: 419-422.
23. Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica 2011; 96: 1067-1071.
24. Sedaghat D, Zakir RM, Choe J, Klapholz M, Saric M., Cardiac amyloidosis in a patient with multiple myeloma: A case report and review of literature. J Clin Ultrasound 2009; 37: 179-184.
25. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: WHO; 2000.
26. Pierce DA, Preston DL., Joint analysis of site-specific cancer risks for the atomic bomb survivors. Radiat Res 1993; 134: 134-142.
27. Myara I, Quenum G, Storogenko M, Tenenhaus D, Guillemain R, Moatti N., Monoclonal and oligoclonal gammopathies in heart-transplant recipients. Clin Chem 1991; 37: 1334-1337.
28. Peest D, Schaper B, Nashan B, Wonigeit K, Raude E, Pichlmayr R, et al. High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation. Transplantation 1988; 46: 389-393.
29. Badley AD, Portela DF, Patel R, Kyle RA, Habermann TM, Strickler JG, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2: 375-382.
30. Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, et al. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation 2013; 95: 519-526.
31. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569.
32. Tsai DE, Aqui NA, Tomaszewski JE, Olthoff KM, Ahya VN, Kotloff RM, et al. Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. Clin Transplant 2005; 19: 644-652.
33. Naina HV, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, et al. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. Am J Nephrol 2012; 35: 365-371.
34. Aguilera NS, Kapadia SB, Nalesnik MA, Swerdlow SH., Extramedullary plasmacytoma of the head and neck: Use of paraffin sections to assess clonality with in situ hybridization, growth fraction, and the presence of Epstein-Barr virus. Mod Pathol 1995; 8: 503-508.
35. Chang ST, Liao YL, Lu CL, Chuang SS, Li CY., Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol 2007; 128: 339-344.
36. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
37. Opelz G, Dohler B., Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
38. Vegso G, Sebestyen A, Paku S, Barna G, Hajdu M, Toth M, et al. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 2007; 31: 1003-1008.
39. Caillard S, Agodoa LY, Bohen EM, Abbott KC., Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: Characteristics, risk factors and prognosis. Transplantation 2006; 81: 888-895.
40. Akashi Y, Yoshizawa N, Kubota T, Oshikawa Y, Oda T, Ishida A, et al. Primary biliary cirrhosis complicated with Sjogren syndrome and multiple myeloma. A case report. Nephron 1996; 73: 730-732.
41. Kaneko H, Endo T, Saitoh H, Katsuta Y, Aramaki T, Hayakawa H., Primary biliary cirrhosis associated with multiple myeloma. Int Med 1993; 32: 802-805.
42. Nasu M, Matsubara O, Kamiyama R, Yamada T, Nishido T, Yamato H., Gastric plasmacytoma and multisystem autoimmune disease. Virchows Arch A Pathol Anat Histol 1984; 404: 109-115.
43. Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor KD., Incidence of cancer in primary biliary cirrhosis: The Mayo experience. Hepatology 1999; 29: 1396-1398.
44. Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF., Cancer risk in primary biliary cirrhosis: A study in northern England. Gut 1999; 45: 756-760.
45. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH., Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010; 10: 720-726.
46. Buhler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405-1409.
47. Dagher F, Sammett D, Abbi R, Tomasula JR, Delaney V, Butt KM., Renal transplantation in multiple myeloma. Case report and review of the literature. Transplantation 1996; 62: 1577-1580.
48. Taheri D, Suzangar H, Heidari F, Feshrakizadeh M, Suzangar M, Dolatkhah S., Skull mass as the first manifestation of recurrent multiple myeloma in a renal transplant patient. J Pak Med Assoc 2012; 62: S76-S78.
49. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 2005; 18: 806-815.